Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide

Doggrell, Sheila Anne (2007). Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. Reviews on Recent Clinical Trials,2(1):77-84.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 4 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide
Author Doggrell, Sheila Anne
Journal Name Reviews on Recent Clinical Trials
Publication Date 2007
Volume Number 2
Issue Number 1
ISSN 1574-8871   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-34248204342
Start Page 77
End Page 84
Total Pages 8
Abstract The obesity epidemic in the developed and developing world is being followed by an epidemic of type 2 diabetes. In type 2 diabetes, subjects cannot manage glucose properly because they do not produce enough insulin, and the peripheral tissues have become resistant to insulin. Glucagon-like peptide 1 (GLP-1) is an intestinal peptide hormone that is secreted in response to food to regulate the postprandial blood glucose concentration. One of the actions of GLP-1 is to stimulate insulin secretion. In subjects with type 2 diabetes, intravenous or subcutaneous GLP-1 stimulated insulin production and decreased blood glucose levels. However, as GLP-1 is rapidly metabolised, it is not suitable for use in most subjects with type 2 diabetes. Exendin-4 is a 39-amino acid peptide that acts as an agonist at the GLP-1 receptor. After subcutaneous administration, synthetic exendin-4 (exenatide) decreased postprandial concentrations of glucose and insulin, and fasting glucose levels in subjects with type 2 diabetes, and the effects lasted several hours. Subsequently, exenatide was been trialled in subjects taking metformin only, a sulfonylurea only, or metformin and a sulfonylurea, and shown to improve glycemic control with few adverse events, initially over 30 weeks, and then extended to 82 weeks. Exenatide may also be as effective as insulin glargine in subjects with type 2 diabetes not adequately controlled with the oral agents. In conclusion, exenatide represents a new and beneficial addition to the medicines used to treat type 2 diabetes.
Keywords Clinical trials
Exenatide
Glucagon-like peptide 1
Insulin glargine
Metformin
Sulfonylureas
Type 2 diabetes
DOI http://dx.doi.org/10.2174/157488707779318053   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 21 Abstract Views  -  Detailed Statistics
Created: Fri, 29 Aug 2014, 18:34:27 CST by Anthony Hornby